Price of revenues for the six months of 2012 was $993,000 compared to $849,000 for the six months of 2011. Selling, general and administrative expenses of $380,000 had been reported for the six months of 2012 in comparison to $342,000 reported for the half a year of 2011, an 11 percent increase. The upsurge in expenses is mainly attributable to personnel and associated benefits needed to comply with the HIPAA 5010 wellness claim format mandated by rules promulgated by the Centers for Medicare & Medicaid Services . Related StoriesRE.WORK showcases potential technology and innovations in deep learning softwareReducing medical center readmissions through Transitional Treatment: an interview with Rani KhetarpalAddressing quality of life needs in prostate cancer: an interview with Professor Louis DenisClaimsnet reported a gross income of $163,000 for the second quarter of 2012, compared with a gross income of $171,000 for the second one fourth of 2011, a 5 percent lower.Avedro to obtain Corneal Collagen Crosslinking Stage III study privileges from Peschke Meditrade Avedro, Inc. Announced it offers signed a definitive contract with today Swiss-centered Peschke Meditrade GmbH to obtain the privileges to its Phase III research of Corneal Collagen Crosslinking for the treating progressive post and keratoconus LASIK ectasia. Corneal crosslinking combines the use of riboflavin with ultraviolet-A light. Jointly, these increase corneal power and stability by inducing brand-new crosslinks between or within collagen fibers.